FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1240-1241 October 14, 1999 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kwiatkowski, T. G. PubMed Citation

To the Editor: Kwiatkowski and colleagues (June 10 issue)¹ report one-year outcomes of the National Institute of Neurological Disorders and Stroke (NINDS) trial of recombinant tissue plasminogen activator (t-PA) for the treatment of stroke. The treatment (thrombolytic drug or placebo) was given once during the first three hours after the onset of stroke. How were patients in the t-PA and placebo groups treated during the subsequent year? Their treatment was probably affected by the results of vascular testing for the cause of the strokes and by the early outcome. The outcome at one year must have been affected by the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wachter, R. M., Flanders, S. A., Fee, C., Pronovost, P. J. (2008). Public Reporting of Antibiotic Timing in Patients with Pneumonia: Lessons from a Flawed Performance Measure. ANN INTERN MED 149: 29-32 [Abstract] [Full Text]